Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lineage Cell Therapeutics reports successful Q4, eyes strategic partnerships

Lineage Cell Therapeutics is advancing with promising programs like OpRegen, focusing on financial discipline and milestone achievements to drive shareholder value in 2023.
Despite net losses in 2022, Lineage's strong cash position, successful clinical outcomes, and strategic partnerships position the company for growth and leadership in cell therapy.

Lineage Cell Therapeutics reports progress in Q1 despite financial challenges

Lineage Cell Therapeutics showcased progress in OpRegen's clinical findings and financial performance in Q1 2023.
The company faces challenges in financials and market education but holds strengths in strategic partnerships and therapeutic advantages.
Opportunities lie in market positioning, collaborations, and continued innovation to drive growth and market adoption for Lineage's therapies.

Lineage Cell Therapeutics reports stable finances and advances key programs

Lineage Cell Therapeutics shows financial stability with strong cash reserves and a strategic focus on advancing key pipeline programs.
Despite challenges in patient enrollment and cell delivery, the company remains innovative and adaptable in exploring gene therapy solutions.
Positive FDA feedback on the OPC1 program and ongoing exploration of partnerships and advancements position Lineage for future growth and success.

Lineage Cell Therapeutics reports strong Q3 performance and eyes growth

Lineage Cell Therapeutics demonstrated financial stability, innovation in cell therapy, and progress in regenerative medicine programs during Q3 2023.
Challenges include study completion, safety concerns, enrollment trends, and strategic resource allocation for future growth.
Opportunities lie in market expansion, collaborations in neurology, therapeutic advancements, and regulatory success for the company.
Overall, Lineage Cell Therapeutics is positioned for growth through strategic partnerships and advancements in regenerative medicine.

Lineage Cell Therapeutics reports stable finances and program advancements

Lineage Cell Therapeutics showcased financial stability, program advancements, and strategic decisions in the Q4 2023 earnings call, emphasizing progress in OpRegen and OPC1 programs.
While facing challenges in managing expenses and uncertainties in program timelines, the company highlighted opportunities in partnerships, patient inclusion, and innovation for future growth.
Analyst questions focused on clinical outcomes, financing decisions, and program updates, reflecting investor interest in OpRegen program advancements and market potential.

Lineage Cell Therapeutics reports Q1 results, highlights partner support

Lineage Cell Therapeutics' Q1 2024 performance reflects revenue challenges but highlights strong partner support and operational preparedness.
The company faces financial losses amid investments in R&D but showcases a commitment to strategic growth and long-term success.
Challenges in revenue generation and data validation are balanced by opportunities in clinical trial efficiency, market demand, and therapeutic expansion.
Overall, Lineage's focus on innovation, partnerships, and operational readiness positions it for potential growth and success in the cell therapy space.

Lineage Cell Therapeutics extends cash runway, advances key programs

Lineage Cell Therapeutics reported financials for Q3 2024, extending cash runway and showcasing progress in key programs.
Strengths include advancements in OpRegen and ReSonance programs, with a strategic focus on manufacturing and partnerships.
Challenges lie in financial performance, maintaining cash discipline, and meeting study endpoints, while opportunities arise from collaborations and program advancements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced the appointment of Anula Jayasuriya, M.D., Ph.D., M.B.A., to the Company's Board of Directors, effective as of May 4, 2021. Dr. Jayasuriya is a successful healthcare private equity executive and venture capitalist with extensive clinical, industry, entrepreneurial, and investmen

Lineage Announces Appointment of Anula Jayasuriya, M.D., PH.D., M.B.A.

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2021 financial and operating results on Thursday, May 13, 2021, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 13, 2021, at 4:30 p.m. Eastern Time/1:30 p.m. Pac

Lineage Cell Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021

Lineage Cell Therapeutics Inc (NYSE: LCTX) has updated interim results from its ongoing Phase 1/2a study of its lead product candidate, OpRegen, for dry age-related macular degeneration (AMD) with geographic atrophy (GA). OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space.

Lineage Cell's Dry Age-Related Macular Degeneration Cell Therapy Associated With Stable Or Improved Vision

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen, were reported at the 2021 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2021). OpRegen is an investigational cell therapy consisting of

OpRegen® Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With Geographic Atrophy

Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lineage Cell (LCTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Chief Executive Officer, will be presenting at the B. Riley Securities' Neuroscience Conference in a virtual fireside chat hosted by B. Riley Equity Research on Wednesday, April 28, 2021 at 1:30 p.m. ET. Interested investors can access the live and archived web

Lineage to Present at the B. Riley Securities' Neuroscience Conference on April 28, 2021

Aptinyx Inc

Bioline RX

Cyclerion Therapeutics Inc

Palatin Technologies

5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced the appointment of Dr. Dipti Amin, MBBS, FFPM, MRCGP, DCPSA, DCH, DRCOG, DGM, to the Company's Board of Directors, effective as of April 20, 2021. Dr. Amin is an experienced Non-Executive Director and a medically trained senior executive with broad expertise in medicine, pharmac

Lineage Announces Appointment of Dr. Dipti Amin to Its Board of Directors

The company announced a license agreement.

Why Lineage Cell Therapeutics Stock Popped Today

Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into a worldwide license and development collaboration agreement with a privately-held Immunomic Therapeutics Inc (ITI) to manufacture and develop a novel candidate using Lineage's VAC allogeneic cancer immunotherapy platform for glioblastoma multiforme, the most aggressive form of brain cancer. ITI will assume full and independent clinical and commercial responsibility and further advancement of the program.

Lineage Stock Gains After Licensing Pact With Immunomic Therapeutics For Cancer Immunotherapy Platform

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #CancerVaccines--VAC/Immunomic Strategic Alliance

Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform

ROCKVILLE, Md. & CARLSBAD, Calif.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today a worldwide license and development collaboration agreement with Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions. The collaboration will generate a novel pr

Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated interim results from a Phase 1/2a study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), will be presented at the 2021 Association for Resea

OpRegen® Data Update to Be Featured at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Christopher D. Riemann, MD

The stock price of Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) increased by over 10% pre-market. This is why it happened.

LCTX Stock Priced Increased Over 10% Pre-Market: Why It Happened

Under a named patient compassionate use approval by the Israeli Ministry of Health, Lineage Cell Therapeutics Inc's (NYSE: LCTX) OpRegen has been used to treat a patient suffering from adult-onset vitelliform macular dystrophy (AVMD) at Hadassah-Hebrew University Medical Center in Jerusalem. The patient was presented with sudden and severe visual acuity decreases in one eye.

Lineage's Lead Candidate Used To Treat Patient With Retinal Disease Under Compassionate Use

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced that a patient suffering from adult-onset vitelliform macular dystrophy (AVMD) had recently been treated with its lead product candidate, OpRegen, at Hadassah-Hebrew University Medical Center in Jerusalem, using a named patient compassionate use approval granted by the Israeli M

Lineage Cell Therapeutics Announces Vitelliform Maculopathy Patient Treated With OpRegen® Under Named Patient Compassionate Use

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced new positive interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space for the tre

Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen® for Dry AMD With Geographic Atrophy

Lineage Cell Therapeutics' (LCTX) CEO Brian Culley on Q4 2020 Results - Earnings Call Transcript

Lineage Cell (LCTX) delivered earnings and revenue surprises of 120.00% and -73.57%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Lineage Cell (LCTX) Tops Q4 Earnings Estimates

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the fourth quarter and full year 2020. Lineage management will host a conference call and webcast today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2020 financial and operating results and to provide

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that it raised $11 million in new capital from sales of its holdings of marketable securities, including shares of OncoCyte Corporation (Nasdaq: OCX) and Hadasit Bio-Holdings (TASE: HDST), as well as $25 million in gross proceeds from its at-the-market (“ATM”) offering. Lineage expec

Lineage Cell Therapeutics Raises $35.9 Million From Sales of Marketable Securities Holdings and an At-the-Market Equity Offering

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2020 financial and operating results on Thursday, March 11, 2021, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 11, 2021, at 4:30 p.m. Eastern

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Chief Executive Officer, will be presenting at the Raymond James 42nd Annual Institutional Investors conference on March 1, 2021 at 11:40am Eastern Time / 8:40am Pacific Time. Mr. Culley will also be presenting at the H.C. Wainwright Global Life Sciences Confer

Lineage to Present at the Raymond James 42nd Annual Institutional Investors Conference on March 1, 2021 and the H.C. Wainwright Global Life Sciences Conference on March 9, 2021

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #CIRM--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced it will be hosting a virtual Investor and Analyst Day on February 22, 2021 at 1:30pm PT / 4:30pm ET to discuss the company's OPC1 program for acute spinal cord injury. Lineage management will be joined by therapeutic area expert Edward Wirth, III, M.D., Ph.D., for an update on OPC1,

Lineage to Host Virtual OPC1 Investor & Analyst Day on February 22, 2021

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #CIRM--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has entered into an exclusive option and license agreement with Neurgain Technologies, Inc. (“Neurgain”), a medical device company that is commercializing technology developed by neurosurgeons at the University of California San Diego (“UC San Diego”). Under the terms of the

News for Lineage Cell Therapeutics Inc Stock (LCTX)